GTBP - GT Biopharma posts interim Phase I/II results from GTB-3550 cancer study

GT Biopharma (GTBP) announces updated interim Phase I/II clinical trial results for the company's lead therapeutic candidate, GTB-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes ((MDS)) and refractory/relapsed acute myeloid leukemia ((AML)).Patients enrolled early in the study (patients 1-4) were treated with doses of GTB-3550 below the anticipated therapeutic dose ((RP2D)) and maximum tolerated dose ((MTD)) to address possible safety concerns.All patients treated at the lower doses exhibited no signs of toxicity, and did not experience any Grade of Cytokine Release Syndrome ((CRS)).In the study, which enrolled a total of 9 patients, the 9th patient, who was treated at the 100mcg/kg/day dose level, achieved a 63.7% reduction in bone marrow blast levels from 22% before therapy to 8% after therapy.All patients treated at higher doses of GTB-3550 did not experience any CRS.MDS is a rare form of bone marrow-related cancer, while AML is a type of cancer in

For further details see:

GT Biopharma posts interim Phase I/II results from GTB-3550 cancer study